Close menu




November 6th, 2020 | 11:04 CET

NEL ASA, Velocity Minerals, Barrick Gold - the next chance!

  • Innovations
Photo credits: pixabay.com

The market does what it wants. Anticipating a worst-case scenario, the markets drew a zig-zag ahead of Tuesday’s election but then settled back into a positive momentum. Dax alone made-up almost 700 points after the index plunged below 12,000 on Wednesday. Although the election spectacle is still not over, the stock markets are rising as if there were no tomorrow. On a positive note, gold has held on to its crucial support zone and is marching dynamically towards its all-time high. A breakout should be a matter of time.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA92258F3007 , NO0010081235 , CA0679011084

Table of contents:


    Gold mines explode

    Due to the rising gold price, first the gold mines of the first row like Barrick Gold, Iam Gold or Newcrest Mining, profit disproportionately. Should the gold price march consistently above the old highs, the leverage will lie instead with the smaller producers. The Canadian exploration Company, Velocity Minerals, is exciting. The Canadians are focused on the discovery and development of gold deposits in Bulgaria. Bulgaria is the country with the largest gold reserves in Europe. The Company's strategy is to develop a low-cost operation where multiple projects deliver gold concentrates to an existing central processing facility.

    Prospective drilling

    Velocity Minerals' flagship project is its 70% interest in Rozino. A PFS, Pre-Feasibility Study, was released last August. Gold mining production could start in 2022, with an after-tax internal rate of return of 27%, per annum! Yesterday, Velocity announced another milestone. In addition to Rozino, another coup appears to have been achieved on the Obichnik project. Both the two new drill holes tested from Premka Zone yielded high mineralization results.

    Golden Future

    President and CEO of Velocity Minerals commented: "The high-grade nature of the gold mineralization is very encouraging and there is more drilling to do at this target. We remain focused on building a multi-asset gold production profile in Bulgaria with a ‘Hub & Spoke’ development strategy. With the recent positive prefeasibility at the Rozino project, we continue to advance our exploration drill programs for resource expansion and definition at Rozino as well as the Obichnik, Makedontsi and Iglika projects."

    Numbers weak thanks to Nikola

    A successful hydrogen Company is in the red. How is that possible? In the case of the Norwegian showpiece Company, NEL ASA, it is due to the participation in the US truck builder Nikola, which still has to defend itself against massive fraud allegations. The negative market value adjustment of NOK 513.3 resulted in an EBITDA of NOK -42.1 million in the third quarter. Reported EBIT was NOK -116.3 million, while the pre-tax loss was NOK -628.6 million, as described above. In terms of turnover, the Scandinavian companies were able to maintain their turnover at NOK 147.7 million, roughly the same level as the previous year (NOK 148.9 million).

    Bright future

    NEL ASA was only able to show the positive trend in the hydrogen industry in terms of the order backlog. With an order backlog of NOK 940.0 million, the Company topped the previous year's figure by a whopping 60%. The coffers are full to the brim with NOK 2.5 billion, the equivalent of around EUR 230 million, to finance further dynamic growth.

    New prestige order

    Earlier this week, NEL ASA announced a significant order. None other than the Spanish utility giant Iberdrola selected the Norwegians as the preferred supplier for a 20-megawatt green fertilizer project in Spain. According to press reports, the plant is scheduled to go into operation as early as 2021. Iberdrola, one of the world's largest electricity suppliers, wants to build the largest environmentally friendly hydrogen plant in cooperation with fertilizer manufacturer, Fertiberia.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Tarik Dede on August 17th, 2026 | 07:55 CEST

    Cancer in Focus: Merck & Co., Vidac Pharma and AstraZeneca

    • Biotechnology
    • Biotech
    • Cancer
    • Innovations
    • Pharma
    • patents

    According to the International Agency for Research on Cancer (IARC), part of the WHO, there are currently around 20.6 million new cancer cases worldwide. The annual death toll is estimated at approximately 10 million people. In recent years, more than 53 million people globally have received a cancer diagnosis. According to the WHO, the number of new cases per year is expected to rise to about 35 million by 2050. Two factors are generally cited as the main drivers: demographic change, with the global population getting older, as well as rising rates of obesity, physical inactivity, smoking and air pollution in many countries. Unsurprisingly, the oncology market is correspondingly lucrative. Oncology is the world's largest pharmaceutical market. There is, however, also some good news: the age-adjusted risk of dying from cancer is declining thanks to earlier detection, targeted therapies and advances in immuno-oncology. Today, we take a closer look at this market through the stocks of Merck & Co., Vidac Pharma and AstraZeneca.

    Read

    Commented by André Will-Laudien on August 5th, 2026 | 07:20 CEST

    Endless NASDAQ Rally – AI Drives Demand for Electric Power and Hydrogen: Nel ASA, dynaCERT, BYD, and ITM Power

    • Hydrogen
    • cleantech
    • Innovations
    • Diesel
    • Retrofitting
    • renewableenergy

    While the relentless tech rally on the NASDAQ races from one historic all-time high to the next thanks to the insatiable AI boom, investors are increasingly focusing on the industry's fundamental Achilles' heel: the enormous electricity demand of AI data centers. As artificial intelligence becomes more deeply embedded in business operations, it not only requires vast amounts of electricity but is also automating routine tasks that were once performed by human workers. This rapid adoption is driving an unprecedented need for reliable power generation. The question is no longer whether additional energy will be needed, but where it will come from. Investors looking toward the future are increasingly seeking the most compelling ESG investment opportunities at the intersection of high-tech innovation and energy production. In addition to expanding nuclear energy, many cleantech solutions are being explored. The e-mobility giant BYD recognized this challenge years ago; today, it dominates the roads worldwide with groundbreaking battery technologies. Complementing the electrification trend is the growing hydrogen economy, where Nel ASA and ITM Power continue to play important roles. At the same time, dynaCERT is rapidly advancing toward broader commercial adoption through an ambitious expansion strategy in Asia, leveraging its emissions-reduction technology. Where are the key catalysts for investors?

    Read

    Commented by André Will-Laudien on August 4th, 2026 | 09:10 CEST

    "Buy the Dip" in the Life Sciences Supercycle: Gerresheimer, Vidac Pharma, Novo Nordisk, and Pfizer as Top Performers of the Future

    • Biotechnology
    • Pharma
    • LifeSciences
    • Cancer
    • Innovations
    • Obesity

    Rising healthcare spending, an aging population, and an unprecedented depth of research are propelling the life sciences sector into a multi-year supercycle. And there are some strong players! Gerresheimer stands out as a brilliant infrastructure asset and a leading provider of high-quality primary packaging. In the field of injections and biologics, the company benefits directly from the explosion of complex therapies and GLP-1 markets. Vidac Pharma is conducting research in the field of cancer and leveraging the Warburg effect for its upcoming studies—a classic high-beta play for investors betting on above-average growth. Novo Nordisk remains the undisputed flagship of the obesity and diabetes wave, and Pfizer is using the current lull in valuations as an opportunity to ignite the next phase of growth with a broad pipeline spanning oncology, vaccines, and new forms of therapy. Who belongs in the portfolio for the next life sciences boom?

    Read